Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-Transplant Graft vs. Host Disease (GvHD) Prophylaxis.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2013
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 24 Mar 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 02 Oct 2005 New trial record.